Phase 4Active, not recruiting
Finerenone Plus SGLT2 Inhibitors in Heart Failure (FIN-SGLT2-HF)
Impact of Finerenone in Combination With Sodium Glucose Cotransporter-2 Inhibitor in Patients With Heart Failure
- Sponsor
- Mansoura University (Academic or other)
- Enrollment
- 60 planned
- Conditions
- Heart Failure
- Interventions
- Finerenone; dapagliflozine
- Ages
- adults, older adults
- Registry
- NCT07351864
Full record on ClinicalTrials.gov
From the registry
The goal of this clinical study is to evaluate whether adding finerenone to standard treatment with a sodium-glucose cotransporter-2 (SGLT2) inhibitor provides additional benefits in patients with heart failure. The main question this study aims to answer is whether the combination of finerenone and an SGLT2 inhibitor improves clinical outcomes and is safe compared to treatment with an SGLT2 inhibitor alone. Participants will receive standard therapy with an SGLT2 inhibitor, with or without the addition of finerenone and will be followed to assess clinical outcomes and safety.
Primary outcomes
- Cardiovascular Mortality and Heart Failure Hospitalization
History
Primary completion
Last registry update
Registered
Started